Press release
The Myopic Macular Degeneration Market Size (7MM) is going to be ~USD 737 million in 2025, and expected to grow with a CAGR of 1.3% during the forecast period (2025-2034)
Myopic Macular Degeneration Drugs Market
Explore In-depth insights into the evolving Myopic Macular Degeneration Market. Download sample report @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Myopic Macular Degeneration Market Report
• As per DelveInsight's estimations, the total diagnosed prevalent cases of Myopic Macular Degeneration in the 7MM were approximately 4.1 million in 2022 and are projected to increase during the forecast period.
• The overall count of individuals diagnosed with Myopic Macular Degeneration in the United States was approximately 1.1 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, Japan accounted for the highest number of Myopic Macular Degeneration diagnosed cases of around 2 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
• Among EU4 and the UK, France had the highest diagnosed prevalent population of Myopic Macular Degeneration, with about 0.27 million cases, followed by Germany and the UK in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In 2022, DelveInsight's analysis of gender-specific diagnosed prevalent Myopic Macular Degeneration cases within the 7MM indicated an approximate distribution of 39% in males and 61% in females.
• The leading Myopic Macular Degeneration Companies such as Roche, Bayer, Regeneron Pharmaceuticals, and others.
• Promising Myopic Macular Degeneration Therapies such as Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and others.
Explore Myopic Macular Degeneration Treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myopic Macular Degeneration Epidemiology Segmentation in the 7MM
• Total Myopic Macular Degeneration Diagnosed Prevalent Cases
• Myopic Macular Degeneration Gender-specific Diagnosed Prevalent Cases
• Total Myopic Macular Degeneration Diagnosed Prevalent cases
Download the report to understand which factors are driving Myopic Macular Degeneration Epidemiology trends @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myopic Macular Degeneration Marketed Drugs
• EYLEA (aflibercept): Bayer/Regeneron Pharmaceuticals
EYLEA is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. EYLEA helps prevent VEGF-A and PLGF from interacting with their natural VEGF receptors in previous clinical trials. While ensuring a commendable safety profile, EYLEA's impact on the market and its cost-effectiveness compared to other treatments are essential considerations. EYLEA, the sole approved mCNV treatment in Japan and Europe with an active patent, dominates the Myopic Macular Degeneration treatment landscape, immune to biosimilar competition.
Myopic Macular Degeneration Emerging Drugs
• VABYSMO (faricimab): Roche
VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signaling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and VEGF-A. Faricimab is not present in the pipeline of Roche for the treatment of mCNV, but the trial is registered on CT, which is in Phase III "not yet recruiting" stage.
Get In-Depth Knowledge on Myopic Macular Degeneration Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Myopic Macular Degeneration Companies
Roche, Bayer, Regeneron Pharmaceuticals, and others.
Myopic Macular Degeneration Market Outlook
Myopic maculopathy (Myopic Macular Degeneration), also named Myopic Macular Degeneration and myopic retinopathy, encompassing macular atrophy, lacquer cracks, and choroidal neovascularization (mCNV), is influenced by age and axial length. Strategies like low concentration atropine and optical interventions aim to curb myopic progression. Currently, no available treatment has been found for myopic maculopathy except for mCNV, creating a pressing need for more treatment options. Present treatments for Myopic Macular Degeneration align with wet AMD approaches, utilizing anti-VEGF medications such as LUCENTIS (with an expired patent) and EYLEA.
Myopic Macular Degeneration Treatment Market Landscape
The Myopic Macular Degeneration (MMD) treatment market is poised for steady growth, driven by the rising global prevalence of high myopia, especially in Asia, which increases the at-risk population for MMD-associated vision loss. Currently, intravitreal anti-VEGF therapies such as ranibizumab, aflibercept, and bevacizumab dominate the treatment landscape for myopic choroidal neovascularization (mCNV), offering proven efficacy in preserving vision. However, the market is now witnessing a shift toward next-generation biologics, extended-release formulations, and innovative delivery platforms aimed at reducing treatment burden and improving compliance.
Get In-Depth Knowledge on Myopic Macular Degeneration Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Myopic Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Myopic Macular Degeneration Companies- Roche, Bayer, Regeneron Pharmaceuticals, and others.
• Myopic Macular Degeneration Therapies- Ranibizumab injection (0.5 mg), VEGF Trap-Eye (BAY86-5321), EYLEA (aflibercept), VABYSMO (faricimab), and others.
• Myopic Macular Degeneration Therapeutic Assessment: Myopic Macular Degeneration Current marketed and Myopic Macular Degeneration emerging therapies
• Myopic Macular Degeneration Market Dynamics: Myopic Macular Degeneration market drivers and Myopic Macular Degeneration market barriers
• Myopic Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Myopic Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Myopic Macular Degeneration Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight's Comprehensive Myopic Macular Degeneration Market Report @ https://www.delveinsight.com/sample-request/myopic-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Key Insights
2. Myopic Macular Degeneration Market Report Introduction
3. Myopic Macular Degeneration Market Overview at a Glance
4. Myopic Macular Degeneration Epidemiology and Market Methodology
5. Executive Summary of Myopic Macular Degeneration
6. Key Events
7. Myopic Macular Degeneration Disease Background and Overview
8. Myopic Macular Degeneration Epidemiology and Patient Population
9. Myopic Macular Degeneration Patient Journey
10. Myopic Macular Degeneration Marketed Therapies
11. Emerging Myopic Macular Degeneration Therapies
12. Myopic Macular Degeneration: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Myopic Macular Degeneration Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Myopic Macular Degeneration Market Size (7MM) is going to be ~USD 737 million in 2025, and expected to grow with a CAGR of 1.3% during the forecast period (2025-2034) here
News-ID: 4256512 • Views: …
More Releases from DelveInsight Business Research LLP
Alopecia Areata Market Size in the 7MM is going to be ~USD 552 million in 2025, …
(Albany, USA) DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Alopecia Areata Market. Download sample report @ https://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Alopecia Areata Market Report
• On 05 November 2025, Eli…
InterVene's Recana System FDA 510(k) Clearance: Tackling Venous In-Stent Resteno …
In a pivotal development for vascular intervention therapies, InterVene, Inc. has announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for its Recana Thrombectomy Catheter System. Designed specifically to treat venous in-stent restenosis (ISR) and native vessel obstructions, Recana marks a significant technological advancement in a domain historically underserved by device-based interventions.
The growing number of venous stent placements globally, the incidence of restenosis and stent failure represents both a…
Idiopathic Membranous Nephropathy Treatment Market Size Expected to Grow Major G …
DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Complicated Urinary Tract Infection (cUTI), historical and forecasted epidemiology as well as the Complicated Urinary Tract Infection (cUTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore Idiopathic Membranous Nephropathy Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
…
Age-related Vision Dysfunction Treatment Market Size Expected to Grow Major Grow …
DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the Age-related Vision Dysfunction Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and…
More Releases for Myopic
Myopic Macular Degeneration Market to Grow at 8.0% CAGR by 2034
Introduction
Myopic Macular Degeneration (MMD), also referred to as myopic maculopathy or pathological myopia, is a progressive retinal condition that occurs in individuals with high myopia. Characterized by degeneration of the macula, choroidal neovascularization, and retinal atrophy, MMD is a leading cause of irreversible vision loss in working-age adults, particularly in East Asia.
The rapid rise in global myopia prevalence-driven by urbanization, lifestyle changes, and increased screen time-has dramatically expanded the patient…
Myopic macular degeneration Market Analysis: Epidemiology Insights, Therapies, C …
In the 7MM, the Myopic Macular Degeneration market size mainly consisted of anti-VEGF therapies and standard of care which generated nearly ~USD 734 million in 2022.
Emerging therapies for Myopic Macular Degeneration, including EYLEA (aflibercept), VABYSMO (faricimab), and others, are anticipated to drive growth in the Myopic Macular Degeneration market in the coming years.
DelveInsight has released a comprehensive report titled "Myopic Macular Degeneration - Market Insights, Epidemiology, and Market Forecast-2034," providing…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
Myopic macular degeneration Market: Epidemiology, Therapies, Companies, DelveIns …
Myopic macular degeneration therapies, such as EYLEA (aflibercept), VABYSMO (faricimab), and others, are expected to boost the Myopic macular degeneration Market in the upcoming years.
DelveInsight has launched a new report on "Myopic macular degeneration - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myopic macular degeneration, historical and forecasted epidemiology as well as the Myopic macular degeneration market trends in the United States, EU5 (Germany,…
Myopic Macular Degeneration Market Forecasted to Surge in Coming Years, 2024-203 …
The Key Myopic Macular Degeneration Companies in the market include - Roche, Bayer, Regeneron Pharmaceuticals, and others.
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth…
Myopic Macular Degeneration Market Report 2034:- Latest FDA, EMA, PDMA, Pipeline …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology and the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Myopic Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Myopic…
